EBR Systems (EBR Systems) EBIT per Share : $-0.11 (TTM As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is EBR Systems EBIT per Share?

EBR Systems's EBIT per Share for the six months ended in Jun. 2023 was $-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for EBR Systems's EBIT per Share or its related term are showing as below:

EBRCZ's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

EBR Systems's EBIT for the six months ended in Jun. 2023 was $-14.13 Mil.

EBR Systems EBIT per Share Historical Data

The historical data trend for EBR Systems's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EBR Systems EBIT per Share Chart

EBR Systems Annual Data

Trend

Dec21

Dec22

Dec23

EBIT per Share

-0.49

-0.12

-0.11

EBR Systems Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	-	-0.06	-0.06	-0.05	-0.05

EBR Systems EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

EBR Systems's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-30.552	/	288.875
=	-0.11

EBR Systems's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-14.132	/	271.114
=	-0.05

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.11

EBR Systems (OTCPK:EBRCZ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

EBR Systems EBIT per Share Related Terms

Thank you for viewing the detailed overview of EBR Systems's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

EBR Systems (EBR Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » EBR Systems Inc (OTCPK:EBRCZ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

EBR:Australia

Address

480 Oakmead Parkway, Sunnyvale, CA, USA, 94085

Website

https://www.ebrsystemsinc.com

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside of the left ventricle of the heart.

EBR Systems (EBR Systems) Headlines

From GuruFocus

WiSE� Technology to Feature in Upcoming APHRS Scientific Session

By PRNewswire PRNewswire • 11-17-2022

EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results Lead to Early Trial Halt for Success

By PRNewswire PRNewswire • 05-22-2023